PeptiDream completed the acquisition of the radiopharmaceutical business from FUJIFILM Toyama Chemical for $273m.

PeptiDream, a biopharmaceutical company, completed the acquisition of the radiopharmaceutical business from FUJIFILM Toyama Chemical, a research biopharmaceutical company, for $273m. Fujifilm has decided that it would be best to transfer FUJIFILM Toyama Chemical's radiopharmaceutical business to PeptiDream for further expansion and growth of such business, which is expected to have synergistic effects on drug discovery in combination with radiopharmaceutical products and PeptiDream’s proprietary peptide drug discovery development technology. FUJIFILM Toyama Chemical's radiopharmaceutical business will be succeeded to the new radiopharmaceutical company established by Fujifilm through absorption-type company split, and all outstanding shares of the new radiopharmaceutical company will be transferred to PeptiDream.